News | 26 August 2011
Sweeping consolidation in the generic drug industry means that fewer companies are left in that market to make up for a shortage. The shortages are forcing health care providers to buy more expensive products in the absence of cheap generics. ...
Click on the link to read the full article at New York Times
(This link will open in a new window)